Lv3
380 积分 2023-01-13 加入
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
3个月前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
HDM1002 in Chinese Adults With Overweight/Obesity: A Randomized, Placebo‐Controlled, Ascending‐Dose Phase 1b Study
3个月前
已完结
The glucagon receptor antagonist LY2409021 has no effect on postprandial glucose in type 2 diabetes
5个月前
已完结
Effect of a glucagon receptor antibody (REMD‐477) in type 1 diabetes: A randomized controlled trial
5个月前
已完结
Efficacy and safety of the glucagon receptor antagonist volagidemab in type‐1 diabetes: A systematic review and meta‐analysis
5个月前
已完结
Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial
5个月前
已完结
Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes
5个月前
已完结
皖公网安备34019202002308
